SpaceX looks set to rise before its July 7 Nasdaq-100 inclusion, as passive index buying, a low float and options-driven gamma squeezes power the stock. CRSP, FTSE Russell and MSCI inclusions also force buying regardless of valuation; above $225 it could reach $300, about $4 trillion. After that, the stance turns bearish: as lockups expire and the float grows from about 5%, early investors' selling should overwhelm buying for a loss-making company, so long-term buyers could wait a year. x.com  … Show more

SpaceX's 912 million-share unlock was a supply event rather than a verdict on the business, and demand has absorbed it. AI segment revenue grew 213% sequentially and adjusted EBITDA turned positive at $1.15B from a $609M loss, showing Wall Street pays the beneficiaries of AI capex. The same float expansion should raise SpaceX's Nasdaq-100 weight at the September rebalance, so with insider selling behind it, passive buying is still to come. x.com 

SpaceX shares are being held up by market makers, not real institutional buying, setting retail up to be the last buyers. The support draws retail FOMO and short sellers whose covering adds another leg up, while pre-IPO institutions slowly sell high and insider lock-ups may unlock early. With a float of only 3-5% of market value, SpotGamma calls it one of the most gamma-sensitive markets in a decade; if call buying pauses, dealers unwind and the stock could fall as fast as it rose. x.com  x.com 

SpaceX options flow turned aggressively bullish ahead of its Nasdaq 100 rebalancing near Friday's close. About $430M of deep in-the-money puts were sold at the bid, mostly expiring the next day, versus about $8M of call buying that included long-dated LEAPS, so selling puts was the dominant bullish bet. x.com  x.com 

SpaceX's Q3 growth and guidance make a small position worth considering despite its still-expensive valuation. Revenue reached $14.58B versus $12.54B expected, up 161% year over year, and Q1 2027 guidance is $33B-$37B. A small start around $144 is under consideration, with more aggressive buying reserved for below the $135 IPO price. x.com 

SpaceX faces a series of large share unlocks that could add selling supply. Another 911 million shares become eligible for sale tomorrow, followed by 328 million on Oct. 24, 319 million on Oct. 26, 1.3 billion in early November and 797 million in December; Elon's 6.4 billion shares become eligible in June 2027. x.com 

Space stocks could regain high-beta flows as SpaceX lockups end and a probable late-November Anthropic IPO threatens AI stocks, much as SpaceX's IPO hurt space names. Hedge funds are overexposed to the Magnificent Seven and underexposed or max short low-quality high beta; falling rates and toppy oil could make the rotation painful for them through 2027. AST SpaceMobile could benefit as intermittent service triggers agreements and Blue Origin possibly returns to the pad in six weeks. x.com  x.com 

SpaceX's Nasdaq inclusion before the July 7 open, one of the fastest ever after an IPO, should bring over $4.5 billion of estimated passive buying from index funds that must buy regardless of price. It follows a Palantir-like post-IPO shakeout from $150 to $215 and back to $165, with $145-165 seen as an accumulation zone and the target still $250+. x.com 

SpaceX's expansion could dilute shareholders and flood the spot market with compute capacity, making 2027 a potential disaster despite this quarter's results. A large share of its proposed capacity would go to the spot market, unlike Meta's internally used capacity; valuing it as if peak spot prices last forever ignores that risk. SpaceX should be down, not up, on that outlook. x.com  x.com  x.com  x.com 

SpaceX's strong earnings give its bullish setup fresh fundamental support. Revenue of $14.58 billion, adjusted EBITDA of $8.81 billion and operating income of $2.79 billion beat expectations, as did connectivity and space revenue; 35 launches and mass to orbit fell short. The shares are also pushing through a cup-and-handle breakout. x.com  x.com